



## Clinical trial results:

**A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)**

### Summary

EudraCT number	2019-003098-24
Trial protocol	DE ES GB FI GR
Global end of trial date	22 August 2023

### Results information

Result version number	v1 (current)
This version publication date	23 August 2024
First version publication date	23 August 2024

### Trial information

#### Trial identification

Sponsor protocol code	CLCZ696I12201
-----------------------	---------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04164732
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 August 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 August 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the effect of LCZ696 on cardiopulmonary exercise test (CPET) parameters in patients with nHCM.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 January 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 7
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Greece: 15
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	United States: 7
Worldwide total number of subjects	46
EEA total number of subjects	32

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	32
From 65 to 84 years	14
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Germany (4 sites), Greece (2 sites), Korea (2 sites), Spain (4 sites), United Kingdom (1 site), United States (5 sites)

### Pre-assignment

Screening details:

Patients who met eligibility criteria entered a single-blind treatment run-in period. Patients who were unable to tolerate either placebo or the 50 mg p.o. b.i.d. dose level, were considered treatment run-in failures and were not randomized into the double-blind, placebo-controlled study

### Period 1

Period 1 title	Treatment run-in period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Run-in (All Participants)
-----------	---------------------------

Arm description:

All patients received oral (p.o.) placebo b.i.d. for 2 weeks, followed by 50 mg p.o. b.i.d. of active LCZ696 for 2 weeks

Arm type	experimental and placebo
Investigational medicinal product name	placebo and LCZ696
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

all patients received oral (p.o.) placebo b.i.d. for 2 weeks followed by 50 mg p.o. of active LCZ696 b.i.d. for 2 weeks.

Number of subjects in period 1	Run-in (All Participants)
Started	46
Completed	40
Not completed	6
Physician decision	1
Screen Failure	1
Adverse event, non-fatal	4

**Period 2**

Period 2 title	Randomized treatment period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	LCZ696 BID
------------------	------------

## Arm description:

Patients were treated with LCZ696. The target dose level was 200 mg p.o. b.i.d.

Arm type	Experimental
Investigational medicinal product name	LCZ696
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Participants started at a LCZ696 100 mg p.o. b.i.d dose. After approximately 14 days, patients who tolerated the 100 mg p.o. b.i.d. dose were up-titrated to 200 mg p.o. b.i.d. dose, whereas those who did not meet the safety criteria were titrated back down to the 50 mg b.i.d. dose

<b>Arm title</b>	Placebo BID
------------------	-------------

## Arm description:

Placebo to LCZ696

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Placebo to LCZ696

<b>Number of subjects in period 2</b>	LCZ696 BID	Placebo BID
Started	20	20
Randomized analysis set	20	20
Per protocol analysis set	19	19
Completed	17	19
Not completed	3	1
Consent withdrawn by subject	1	-
Adverse event, non-fatal	1	-
Protocol Deviation	1	1



## Baseline characteristics

### Reporting groups

Reporting group title	Treatment run-in period
-----------------------	-------------------------

Reporting group description: -

Reporting group values	Treatment run-in period	Total	
Number of subjects	46	46	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	32	32	
From 65-84 years	14	14	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	55.7		
standard deviation	± 13.42	-	
Sex: Female, Male			
Units: Participants			
Female	12	12	
Male	34	34	
Race/Ethnicity, Customized			
Units: Subjects			
Asian	6	6	
White	40	40	

## End points

### End points reporting groups

Reporting group title	Run-in (All Participants)
Reporting group description: All patients received oral (p.o.) placebo b.i.d. for 2 weeks, followed by 50 mg p.o. b.i.d. of active LCZ696 for 2 weeks	
Reporting group title	LCZ696 BID
Reporting group description: Patients were treated with LCZ696. The target dose level was 200 mg p.o. b.i.d.	
Reporting group title	Placebo BID
Reporting group description: Placebo to LCZ696	

### Primary: Change from baseline in peak VO2 as measured by cardiopulmonary exercise test (CPET)

End point title	Change from baseline in peak VO2 as measured by cardiopulmonary exercise test (CPET)
End point description: The primary analysis assessed the effect of LCZ696 on the change from baseline in peak Volume of Oxygen (VO2) (ml/kg/min) at week 50 compared to placebo, where baseline peak VO2 came from the screening/baseline CPET. An increase in peak VO2 (mL/kg/min)/positive change is considered beneficial for the patient.	
End point type	Primary
End point timeframe: Baseline to 50 weeks	

End point values	LCZ696 BID	Placebo BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	19		
Units: mL/kg/min				
least squares mean (confidence interval 90%)	1.00 (-0.22 to 2.23)	0.39 (-0.80 to 1.58)		

### Statistical analyses

Statistical analysis title	model-based arithmetic mean estimates
Comparison groups	LCZ696 BID v Placebo BID
Number of subjects included in analysis	37
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5506
Method	longitudinal mixed effects (MMRM) model
Parameter estimate	Median difference (net)
Point estimate	0.61



Confidence interval	
level	Other: 80 %
sides	2-sided
lower limit	-0.71
upper limit	1.94

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 54 weeks.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Run-In Period Placebo
-----------------------	-----------------------

Reporting group description:

Run-In Period Placebo

Reporting group title	Double-blind period placebo
-----------------------	-----------------------------

Reporting group description:

Double-blind period placebo

Reporting group title	Total
-----------------------	-------

Reporting group description:

Total

Reporting group title	Double-blind period LCZ696 100 mg
-----------------------	-----------------------------------

Reporting group description:

Double-blind period LCZ696 100 mg

Reporting group title	Double-blind period LCZ696 200 mg
-----------------------	-----------------------------------

Reporting group description:

Double-blind period LCZ696 200 mg

Reporting group title	Double-blind period LCZ696
-----------------------	----------------------------

Reporting group description:

Double-blind period LCZ696

Reporting group title	Run-In LCZ696 50 mg
-----------------------	---------------------

Reporting group description:

Run-In LCZ696 50 mg

Reporting group title	Double-blind period LCZ696 50 mg
-----------------------	----------------------------------

Reporting group description:

Double-blind period LCZ696 50 mg

Serious adverse events	Run-In Period Placebo	Double-blind period placebo	Total
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	3 / 46 (6.52%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Bundle branch block left			

subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bundle branch block right			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Double-blind period LCZ696 100 mg	Double-blind period LCZ696 200 mg	Double-blind period LCZ696
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 20 (5.00%)	2 / 17 (11.76%)	3 / 20 (15.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from	0	0	0

adverse events			
Cardiac disorders			
Bundle branch block left			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 20 (5.00%)	0 / 17 (0.00%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bundle branch block right			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Run-In LCZ696 50 mg	Double-blind period LCZ696 50 mg	
Total subjects affected by serious adverse events			

subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Cardiac disorders			
Bundle branch block left			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 4.99 %

<b>Non-serious adverse events</b>	Run-In Period Placebo	Double-blind period placebo	Total
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 46 (8.70%)	10 / 20 (50.00%)	26 / 46 (56.52%)
Vascular disorders			
Hypotension subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	4 / 46 (8.70%)
occurrences (all)	0	0	4
General disorders and administration site conditions			
Oedema subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences (all)	0	0	1
Chest pain subjects affected / exposed	0 / 46 (0.00%)	1 / 20 (5.00%)	1 / 46 (2.17%)
occurrences (all)	0	1	1
Asthenia subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences (all)	0	0	1
Chronic obstructive pulmonary disease subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences (all)	0	0	1
Sleep apnoea syndrome subjects affected / exposed	0 / 46 (0.00%)	1 / 20 (5.00%)	2 / 46 (4.35%)
occurrences (all)	0	1	2
Investigations			
SARS-CoV-2 test positive subjects affected / exposed	0 / 46 (0.00%)	0 / 20 (0.00%)	1 / 46 (2.17%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			

Foreign body in eye subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 20 (5.00%) 1	1 / 46 (2.17%) 1
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Syncope subjects affected / exposed occurrences (all)  Tension headache subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2  0 / 46 (0.00%) 0  0 / 46 (0.00%) 0	1 / 20 (5.00%) 1  0 / 20 (0.00%) 0  0 / 20 (0.00%) 0	5 / 46 (10.87%) 5  1 / 46 (2.17%) 2  1 / 46 (2.17%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 2
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)  Gastrointestinal sounds abnormal subjects affected / exposed occurrences (all)  Gastric disorder subjects affected / exposed occurrences (all)  Diarrhoea	1 / 46 (2.17%) 1  0 / 46 (0.00%) 0  0 / 46 (0.00%) 0	0 / 20 (0.00%) 0  0 / 20 (0.00%) 0  0 / 20 (0.00%) 0	2 / 46 (4.35%) 2  1 / 46 (2.17%) 1  1 / 46 (2.17%) 1

subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 20 (0.00%) 0	3 / 46 (6.52%) 3
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	2 / 20 (10.00%) 2	2 / 46 (4.35%) 2
Skin and subcutaneous tissue disorders Angioedema subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Renal and urinary disorders Renal impairment subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Nocturia subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 20 (0.00%) 0	2 / 46 (4.35%) 2
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 20 (5.00%) 1	1 / 46 (2.17%) 1
Diarrhoea infectious subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Cystitis subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 20 (5.00%) 1	1 / 46 (2.17%) 1
COVID-19 subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	5 / 20 (25.00%) 5	5 / 46 (10.87%) 5



Diverticulitis subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 2
Metabolism and nutrition disorders Abnormal loss of weight subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 20 (0.00%) 0	1 / 46 (2.17%) 1
Gout subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 20 (5.00%) 1	1 / 46 (2.17%) 1

<b>Non-serious adverse events</b>	Double-blind period LCZ696 100 mg	Double-blind period LCZ696 200 mg	Double-blind period LCZ696
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 20 (30.00%)	7 / 17 (41.18%)	12 / 20 (60.00%)
Vascular disorders Hypotension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 17 (11.76%) 2	3 / 20 (15.00%) 3
General disorders and administration site conditions Oedema subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Chest pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0	0 / 20 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0	1 / 20 (5.00%) 1
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0	1 / 20 (5.00%) 1
Sleep apnoea syndrome			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Investigations SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Injury, poisoning and procedural complications Foreign body in eye subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0	0 / 20 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Syncope subjects affected / exposed occurrences (all)  Tension headache subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0  0 / 20 (0.00%) 0  0 / 20 (0.00%) 0	2 / 17 (11.76%) 2  1 / 17 (5.88%) 2  1 / 17 (5.88%) 1	2 / 20 (10.00%) 2  1 / 20 (5.00%) 2  1 / 20 (5.00%) 1
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0	1 / 20 (5.00%) 1
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0	1 / 20 (5.00%) 1
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)  Gastrointestinal sounds abnormal	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1

subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 17 (0.00%) 0	1 / 20 (5.00%) 1
Gastric disorder subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Diarrhoea subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0	0 / 20 (0.00%) 0
Skin and subcutaneous tissue disorders Angioedema subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Renal and urinary disorders Renal impairment subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Nocturia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 17 (0.00%) 0	0 / 20 (0.00%) 0
Diarrhoea infectious subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 17 (5.88%) 1	1 / 20 (5.00%) 1

Cystitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 17 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 20 (0.00%)	0 / 17 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 17 (5.88%)	1 / 20 (5.00%)
occurrences (all)	0	1	1
Metabolism and nutrition disorders			
Abnormal loss of weight			
subjects affected / exposed	1 / 20 (5.00%)	0 / 17 (0.00%)	1 / 20 (5.00%)
occurrences (all)	1	0	1
Gout			
subjects affected / exposed	0 / 20 (0.00%)	0 / 17 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Run-In LCZ696 50 mg	Double-blind period LCZ696 50 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 43 (9.30%)	1 / 1 (100.00%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 43 (2.33%)	1 / 1 (100.00%)	
occurrences (all)	1	1	
General disorders and administration site conditions			
Oedema			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Chest pain			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Asthenia			
subjects affected / exposed	0 / 43 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			

Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Sleep apnoea syndrome subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Investigations SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Injury, poisoning and procedural complications Foreign body in eye subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Syncope subjects affected / exposed occurrences (all)  Tension headache subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0  0 / 43 (0.00%) 0  0 / 43 (0.00%) 0	0 / 1 (0.00%) 0  0 / 1 (0.00%) 0  0 / 1 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Ear and labyrinth disorders			

Vertigo subjects affected / exposed occurrences (all)	1 / 43 (2.33%) 1	0 / 1 (0.00%) 0	
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Gastrointestinal sounds abnormal subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Gastric disorder subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	1 / 43 (2.33%) 1	0 / 1 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Skin and subcutaneous tissue disorders Angioedema subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Renal and urinary disorders Renal impairment subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Nocturia subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Infections and infestations			

Urinary tract infection subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Diarrhoea infectious subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Cystitis subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
COVID-19 subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Diverticulitis subjects affected / exposed occurrences (all)	1 / 43 (2.33%) 1	0 / 1 (0.00%) 0	
Metabolism and nutrition disorders Abnormal loss of weight subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	
Gout subjects affected / exposed occurrences (all)	0 / 43 (0.00%) 0	0 / 1 (0.00%) 0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 February 2020	<ul style="list-style-type: none"><li>• Protocol summary<ul style="list-style-type: none"><li>- Key inclusion and exclusion criteria were corrected to reflect the criteria listed in Section 5 of the protocol.</li></ul></li><li>• Section 3 Study design<ul style="list-style-type: none"><li>- Clarified the use of safety criteria to assess tolerability of study medication.</li></ul></li><li>• Section 4.2 Rationale for selection of patient population<ul style="list-style-type: none"><li>- Added rationale for the NT-proBNP cutoff required to screen asymptomatic patients.</li></ul></li><li>• Section 4.7 Risks and benefits<ul style="list-style-type: none"><li>- Clarified risk of fetal harm by study medication if women of childbearing potential become pregnant while on study medication.</li></ul></li><li>• Section 5.1 Inclusion criteria<ul style="list-style-type: none"><li>- Inclusion criteria 4 has been updated to allow asymptomatic/NYHA Class I patients with peak VO2 of 80% to enroll in the study to harmonize with exclusion criteria 4.</li></ul></li><li>• Section 5.2 Exclusion criteria<ul style="list-style-type: none"><li>- Exclusion criteria 3 was clarified to exclude only those patients with a history of atrial fibrillation within 6 months of the screening/baseline visit.</li></ul></li><li>• Section 8 Visit schedule and assessments<ul style="list-style-type: none"><li>- Corrected a typographical error to make clear the requirement for recording adverse events during the screening/baseline period.</li></ul></li><li>• Section 8.4.4 Laboratory evaluations<ul style="list-style-type: none"><li>- Added clarification that plasma samples instead of serum samples can be collected for local laboratory analysis as per local practice.</li></ul></li><li>• Section 10.2.1 Liver safety monitoring<ul style="list-style-type: none"><li>- Correction made to indicate that results of local liver chemistry tests associated with a liver event should be recorded in source documents rather than in the CRF.</li></ul></li><li>• Section 12.7 Interim Analysis<ul style="list-style-type: none"><li>- Added clarification that the planned interim analysis will also include review of safety data.</li></ul></li></ul>
01 April 2022	<ul style="list-style-type: none"><li>• Section 2 Objectives and Endpoints<ul style="list-style-type: none"><li>- Added information in Table 2.1 (Objectives and related endpoints) about collection of NYHA as an exploratory endpoint.</li></ul></li><li>• Section 5.1 Inclusion criteria<ul style="list-style-type: none"><li>- Added additional text to emphasize to sites that Informed Consent must be signed prior to discontinuation of ACE-I/ARB during the &gt;36 hour washout period, if applicable.</li></ul></li><li>• Section 8 Visit schedule and assessments<ul style="list-style-type: none"><li>- Added the specific time points in Table 8.1 for data collection of NYHA class information at screening/baseline and Week 50 or EOS (if the patient discontinues the study prior to the Week 50 assessment).</li><li>- Added Table 8.2 NYHA functional class table with standard descriptions of each functional class</li></ul></li><li>• Section 10.1.3 SAE reporting<ul style="list-style-type: none"><li>- Added additional text for clarification on investigator reporting timelines for SAEs</li></ul></li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats



None reported